[Skip to Content]
[Skip to Content Landing]
July 1997

Iron Overload Is a Risk Factor for Zygomycosis

Author Affiliations

From the Royal Victorian Eye and Ear Hospital (Dr McNab) and the Department of Anatomical Pathology, St Vincent's Hospital, Fitzroy (Dr McKelvie), Melbourne, Australia.

Arch Ophthalmol. 1997;115(7):919-921. doi:10.1001/archopht.1997.01100160089018

Well-recognized risk factors for zygomycosis include diabetic ketoacidosis, immunocompromise, and deferoxamine therapy for iron or aluminum overload, usually in patients undergoing kidney dialysis. We report a case of fatal nasal-orbital-cerebral zygomycosis in an 82-year-old man with known myelodysplasia and well-controlled diabetes. He was not receiving deferoxamine. Despite radical surgery and amphotericin B therapy, he died; primary hemochromatosis with gross iron overload was found post mortem. Experimental evidence suggests iron overload without deferoxamine therapy may be a risk factor for zygomycosis; the findings in this case would support this hypothesis.

Boelaert JR, Fenves AZ, Coburn JW.  Deferoxamine therapy and mucormycosis in dialysis patients: report of an international registry .  Am J Kidney Dis . 1991;18:660-667.Crossref
Slade MP, McNab AA.  Fatal mucormycosis therapy associated with deferoxamine .  Am J Ophthalmol . 1991;112:594-595.
Yohai RA, Bullock JD, Aziz AA, Markert RJ.  Survival factors in rhino-orbital-cerebral mucormycosis .  Surv Ophthalmol . 1994;39:3-22.Crossref
Artis WM, Fountain JA, Delcher AK, et al.  A mechanism of susceptibility to mucormycosis in diabetic ketoacidosis: transferrin and iron availability .  Diabetes . 1982;31:109-114.Crossref
Van Cutsem J, Boelaert JR.  Effects of deferoxamine, feroxamine and iron on experimental mucormycosis .  Kidney Int . 1989;36:1061-1068.Crossref
Abe F, Inaba H, Katoh T, Hotchi M.  Effects of iron and desferrioxamine on Rhizopus infection .  Mycopathologia . 1990;110:87-91.Crossref